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The UT-A1 urea transporter is crucial to the kidney’s ability to generate concentrated
urine. Native UT-A1 from kidney inner medulla (IM) is a heavily glycosylated protein with
two glycosylation forms of 97 and 117 kDa. In diabetes, UT-A1 protein abundance,
particularly the 117 kD isoform, is significantly increased corresponding to an increased
urea permeability in perfused IM collecting ducts, which plays an important role
in preventing the osmotic diuresis caused by glucosuria. However, how the glycan
carbohydrate structure change and the glycan related enzymes regulate kidney urea
transport activity, particularly under diabetic condition, is largely unknown. In this
study, using sugar-specific binding lectins, we found that the carbohydrate structure of
UT-A1 is changed with increased amounts of sialic acid, fucose, and increased glycan
branching under diabetic conditions. These changes were accompanied by altered
UT-A1 association with the galectin proteins, β-galactoside glycan binding proteins. To
explore the molecular basis of the alterations of glycan structures, the highly sensitive
next generation sequencing (NGS) technology, Illumina RNA-seq, was employed to
analyze genes involved in the process of UT-A1 glycosylation using streptozotocin
(STZ)—induced diabetic rat kidney. Differential gene expression analysis combining
with quantitative PCR revealed that expression of a number of important glycosylation
related genes were changed under diabetic conditions. These genes include the
glycosyltransferase genes Mgat4a, the sialylation enzymes St3gal1 and St3gal4 and
glycan binding protein galectin-3, -5, -8, and -9. In contrast, although highly expressed
in kidney IM, the glycosyltransferase genes Mgat1, Mgat2, and fucosyltransferase
Fut8, did not show any changes. Conclusions: In diabetes, not only is UT-A1 protein
abundance increased but the protein’s glycan structure is also significantly changed.
UT-A1 protein becomes highly sialylated, fucosylated and branched. Consistently, a
number of crucial glycosylation related genes are changed under diabetic conditions. The
alteration of these genes may contribute to changes in the UT-A1 glycan structure and
therefore modulate kidney urea transport activity and alleviate osmotic diuresis caused
by glucosuria in diabetes.
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Introduction
Urea is an important solute that contributes to the inner
medullary osmolarity gradient in the kidney. The major
mechanism for delivering urea to the inner medullary
interstitium is urea reabsorption from the terminal inner
medullary collecting duct (IMCD) mediated by the UT-A1 urea
transporter. This process is mainly controlled by vasopressin
in vivo. The importance of the urea transporter is evident in the
UT-A1/UT-A3 knockout mouse, which demonstrates impaired
urea clearance, reduced urinary concentration ability (Fenton
et al., 2004), and hypertension (Jacob et al., 2008).
Native UT-A1 from kidney inner medulla (IM) is a heavily
glycosylated protein with two glycosylated forms of 97 and
117 kDa; both are derived from a single 88-kDa core protein
(Bradford et al., 2001; Chen et al., 2011). The 117-kDa form
is fully glycosylated and contains N-glycans with poly-N-
acetyllactosamine (poly-LacNAc) terminal processing, whereas
the 97-kDa form is a hybrid form containing primarily the
high mannose type of immature N-glycans (Chen et al.,
2011). Interestingly, the 117 kDa form of UT-A1 increases
dramatically in several states associated with decreased urea
concentration, such as streptozotocin (STZ)-induced diabetes
mellitus (Kim et al., 2003), a low-protein diet (Terris et al.,
1998), hypercalcemia (Sands et al., 1998), water diuresis (Terris
et al., 1998), and furosemide administration (Terris et al.,
1998). A functional study using tubule perfusion showed that
the increased 117 kDa glycoform in the IM is associated with
increased urea transport activity (Pech et al., 2005). This suggests
that changes in the relative abundance of the 97 and 117 kDa
forms of UT-A1 may have important regulatory roles for UT-
A1 function. Mutation of this protein revealed that N-linked
glycosylation plays an important role in UT-A1 trafficking,
protein stability and bioactivity (Chen et al., 2006). Loss of
N-linked glycosylation significantly reduces urea transporter
UT-A1 response to vasopressin (Chen et al., 2006). However,
the underlying mechanism by which glycosylation affects these
processes remains largely undetermined.
Asn (N)-linked glycosylation is generally a co-translational
event that involves addition of a 14-sugar core oligosaccharide
chain (Glc3Man9GlcNAc2) to consensus sites (Asn-X-Ser/Thr)
within the nascent polypeptide in the endoplasmic reticulum
(ER). Remodeling or maturation of the high mannose core
oligosaccharide is a post-translational modification that occurs
during transit of the glycoprotein from the ER through the
Golgi complex and trans- Golgi network (TGN). Conversion
of the high mannose core to a more complex type involves
removal of glucose (Glc) and mannose (Man), and addition of
sugars such as N-acetylglucosamine (GlcNAc), galactose (Gal),
fucose (Fuc), and sialic acid. A specific enzyme carries out
each step in the remodeling process, and the structure of a
complex N-glycan on individual proteins can greatly vary among
Abbreviations: IM, inner medulla; IMCD, inner medullary collecting duct; STZ,
streptozotocin; CRD, carbohydrate recognition domain; qRT-PCR, quantitative
real time PCR; Mgat, GlcNActransferase; St3gal, ST3 β-galactoside α-2,3-
sialyltransferase; St6galnac, ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-
acetylgalactosaminide α-2,6-sialyltransferase; St8sia, ST8 α-N-acetyl-neuraminide
α-2,8-sialyltransferase; Neu, neuraminidases; Fut, fucosyltransferase.
different tissues, organisms, and disease states due to the levels
of enzyme expression. More than 200 enzymes participate in
protein glycosylation and remodeling (Spiro, 2002; Nairn et al.,
2008), thereby determining the abundance and diversity of
individual N-glycan structures, making glycan maturation one of
the most complex post translational modifications.
The recent development of next-generation RNA sequencing
(RNA-Seq) technology provides a powerful method for profiling
the entire transcriptome in small samples. Compared to
hybridization-based methodologies of transcriptome analysis,
RNA-Seq is not restricted to previously known transcripts and
has low background, no hybridization bias, higher specificity,
sensitivity, accuracy, and, importantly, provides quantitative
information on mRNA transcript number (Wang et al., 2009;
Hackett et al., 2012; Huber-Keener et al., 2012; Song et al.,
2012). This new technology makes it suitable for us to analyze
the molecular basis of UT-A1 glycan maturation both under
physiological and pathophysiological situations.
In diabetes, kidney urea transport activity and urine
concentration ability are markedly changed in response to
increased glucose in urine and water loss (Kim et al., 2003;
Pech et al., 2005). In the present study, using a differential
sugar-specific binding protein—lectin, we discovered that the
carbohydrate structure of UT-A1 is significantly changed
under diabetic conditions. UT-A1 becomes highly sialylated,
fucosylated, and branched. In addition, consistent with the
alteration of glycan structure, UT-A1 binding to galectin
proteins is also changed. To obtain transcript profiles of the
glycan-modifying enzymes responsible for UT-A1 N-glycan
structure changes in diabetes, we took advantage of Illumina
mRNA sequencing (RNA-seq) technology and investigated gene
expression in kidney IM from STZ-induced diabetic rats. Our
goal of the RNA-seq analysis was to, at the transcript level, inspect
whether the enzymes involved in the glycosylation processes
of sialylation, fucosylation, glycan chain branching and glycan
binding to galectin proteins, were altered in normal and diabetic
kidney.
Materials and Methods
STZ Rat Models
Male Sprague-Dawley rats, 3 months (∼150 g), were purchased
from Charles River Laboratories. We used the well-established
streptozotocin (STZ)-induced diabetic rat model (Kim et al.,
2003; Chen et al., 2011). Rats were injected with STZ (62.5mg/kg
body weight prepared fresh in 0.1M citrate buffer, pH 4.0) or
vehicle into the tail vein. Diabetes was confirmed by measuring
blood glucose (One Touch Profile Diabetes Tracking Kit) 24 h
after STZ injection. At 15 d after injection, rats were sacrificed
by decapitation. The terminal half of the IM (IM tip) was
dissected from kidney and used for protein and RNApreparation.
All animal protocols were approved by the Emory University
Institutional Animal Care and Use Committee (IACUC).
Lipid Raft Preparation and Lectin Pulldown
Cell membrane lipid raft fractions were used for lectin
pulldown experiments. Lipid rafts from freshly isolated IM tip
were prepared with a 5–40% sucrose discontinuous gradient
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ultracentrifugation protocol as described (Huang et al., 2010;
Chen et al., 2011). Equal amounts of pooled lipid raft fractions
(fractions 2–4) were incubated with 30µl of an agarose-
conjugated lectin suspension at 4◦C overnight. After washing,
the precipitated proteins were subjected to Western blotting
with UT-A1 antibody. All the agarose-conjugated lectins were
purchased from Vector Laboratories. The lectins used in this
study are concanavalin A (Con A), galanthus nivalis lectin
(GNL), wheat germ agglutinin (WGA), tomato lectin, datura
stramonium lectin (DSL), phaseolus vulgaris leukoagglutinin
(PHA-L), sambucus nigra lectin (SNA), maackia amurensis lectin
II (MAL II), and aleuria aurantia lectin (AAL).
GST-Galectin Fusion Protein Preparation and
Pulldown
The cDNAs for Gal-1, -3, -4, -7, -8, -9N, and -9C were subcloned
into the bacterial vector pGEX-6P-1 and the GST fusion galectin
proteins were prepared from bacteria as described (Poland
et al., 2011). The fusion proteins were first affinity purified on
glutathione-conjugated Sepharose and then lactose-conjugated
Sepharose to insure that galectins were active. Equal amount of
cell membrane fractions from rat IM were incubated with freshly
prepared GST-galectin proteins bound to glutathione-conjugated
beads for 1 h at 4◦C. The beads were washed with buffer
A (0.05M Tris-HCl, pH 8, 150mM NaCl) containing 14mM
β-mercaptoethanol, and then sequentially eluted with buffer
containing 0.1M sucrose (negative control) and 0.1M lactose
(specific-binding). The eluted proteins were analyzed byWestern
blot with anti-UT-A1 antibody. NIH ImageJ software was used to
quantify the band density from three independent experiments.
Data were expressed as mean ± SD. Statistical analysis of the
data was performed by One-Way ANOVA. Differences were
considered as significant at ∗P < 0.05 or ∗∗P < 0.01.
IM Tip RNA Isolation and cDNA Synthesis
For the RNA-seq study, the total RNA from rat IM tip was
extracted using Trizol Reagent (Invitrogen). The RNA samples
were purified using an RNeasy Mini Kit (Qiagen). Quantification
and purity assessment of the RNA samples were determined on a
NanoDrop Spectrophotometer (Nano-Drop Technologies). RNA
quality was assessed with an Agilent Bioanalyzer 2100. Equal
amounts of purified mRNA was transcribed to cDNA using a
SMARTer PCR cDNA Synthesis Kit (Clontech Cat#634925).
Library Preparation and Illumina HiSeq2000
Sequencing
The cDNAs (Ctrl n = 3, STZ n = 3) for high-throughput
sequencing were fragmented by DNase I and ligated to Illumina
adapters. These adapter-ligated cDNA fragments were amplified
and sequenced on the Illumina HiSeq2000 sequencer.
RNA-seq Data Processing
Raw sequence reads from the FASTQ files from six samples
were mapped against rat reference genome rn4 with STAR2.3.1t
(Dobin et al., 2013). Only the uniquely mapped reads were used
to calculate the numbers of reads per gene. The counts of the
control group and the STZ group were tabulated in a table.
This table was then fed to DESeq (Anders and Huber, 2010)
for normalization and identification of differentially expressed
genes between these two groups using the standard workflow.
To correct for multiple hypothesis testing, the Benjamini–
Hochberg procedure was used with an FDR cutoff of 0.05.
Functional category and pathway analysis of diabetes-dependent
changed genes were performed using IPA (Ingenuity Pathways
Analysis, www.ingenuity.com). Unfortunately, the IPA analysis
did not pick up the glycosylation-related genes; either the
data set does not have such genes or the IPA may not have
glycosylation pathways. We therefore manually searched and
summarized those genes involving glycosylation process of
sialylation, fucosylation, glycan chain branching, and glycan
binding protein galectins from the RNA-seq data.
Quantitative Real Time PCR (qRT-PCR)
Quantitative real-time PCR were performed as we described
before (Chen et al., 2010). The complementary DNAs from total
RNA samples were synthesized by reverse transcription (RT)
with SuperScript reverse transcriptase (BD Bioscience). Gene-
specific primers were designed to generate amplicons of length
100–250 nucleotides by using the Invitrogen Primer program.
Prior to real-time PCR, a single amplified product of the expected
size was confirmed by regular PCR and gel electrophoresis. All
amplified products were subcloned into TA vector and further
verified by DNA sequencing. Real-time PCR were carried out
using the Bio-Rad iCycler Real-Time Detection System with a
three-step protocol. Cycling conditions were set as 95◦C for
3min, followed by 40 cycles of 30 s at 95◦C, 30 s at 55◦C, and 30 s
at 72◦C. Fluorescence of the amplificates was detected with the
iQTM SYBR Green Supermix (Bio-Rad). Data were normalized
using the ratio of GAPDH and analyzed by iCycler software3.0
(Bio-Rad). Primers specific for each of the genes are shown
in Supplemental Table S4. Significance was determined using a
Student’s t-test for each targeted gene.
Results
UT-A1 is Highly Sialylated, Fucosylated, and
Branched in Diabetes
Cell membrane UT-A1 is primarily localized in lipid raft
microdomains (Chen et al., 2011). To assess differences in the N-
glycan structure of UT-A1 in control and STZ rat IM, we isolated
lipid raft membrane fractions as previously described and used
this material for lectin binding assays as described in Materials
andMethods. As shown in Figure 1A, the 97 kDa form of UT-A1
from control rat IM rafts bound primarily to Con A and GNL
(mannose-specific) and WGA (GlcNAc specific), but was not
detected in the GNL or Con A bound fractions of the STZ rats.
The 117 kDa form of UT-A1 bound primarily to WGA (GlcNAc
specific), tomato lectin (poly-N-acetyllactosamine), and DSL
(repeating N-acetyllactosamine). Interestingly, the proportion of
UT-A1 bound to SNA, AAL, and PHA-L form in the STZ rat
IM is notably increased when compared to the proportion in
the control rat IM. The increased UT-A1 binding to SNA, AAL,
and PHA-L is not due to the protein overloading or extended
exposure time since the UT-A1 bound to Con A and GNL
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FIGURE 1 | Lectin pulldown assays. (A) Cell membrane lipid raft fractions
isolated from control or STZ-diabetic rat IM tip were pooled and incubated
with 30µl of indicated agarose-bound lectins at 4◦C overnight. After washing,
the lectin precipitated samples were analyzed by immunoblotting with
anti-UT-A1 antibody. (B) Densitometry analysis of UT-A1 protein bands from
three separate experiments (n = 3). Each lectin precipitated UT-A1 was
normalized with UT-A1 from input proteins (means ± SD, *P < 0.05,
**P < 0.01, NS, no significance).
is not increased. On the contrary, there is a decrease of the
lower glycosylated 97 kDa UT-A1 pulled down by Con A and
GNL under diabetic situations. Binding of 117 kDa UT-A1 to
SNA, AAL, and PHA-L is consistent with the presence of sialic
acid, fucose, and tetra-antennary branched glycans, respectively.
Figure 1B is the densitometry analysis of lectin bound UT-A1
of control and STZ rat IM samples from three independent
experiments.
Increased Association of Galectin-3, 7, 8, 9 with
117kDa UT-A1 in Diabetes
Galectins are a group of small lectin-like proteins (14–30 kDa)
that bind β-galactose-containing glycoconjugates. Each galectin
has unique binding specificities (Poland et al., 2011). To
investigate whether the change of the UT-A1 glycan structure
under diabetic conditions would result in alteration of UT-A1
binding to galectin proteins, we performed the GST-galectin
pulldown assay with control and STZ rat IM samples as described
in Materials and Methods. GST-galectin proteins pre-bound to
glutathione beads were incubated with equal amounts of lipid
raft membrane fractions from kidney IM and eluted with lactose.
FIGURE 2 | GST-galectin pulldown assays. (A) Equal amount of cell
membrane fractions from rat IM tip were incubated with freshly prepared
GST-galectin proteins for 1 h at 4◦C. After washing with buffer A containing
14mM β-mercaptoethanol and buffer containing 0.1M sucrose, the galectin
specific binding proteins were eluted by 0.1M lactose (specific-binding) and
subsequently analyzed by Western blot with UT-A1 antibody (Top). The same
membrane was stained by Coomassie brilliant blue to verify GST fusion
galectin proteins (Bottom). (B) Densitometry analysis of UT-A1 protein bands
from three separate experiments (n = 3). Each GST-galectin precipitated
UT-A1 was normalized with UT-A1 from input (means ± SD, *P < 0.05,
**P < 0.01, NS, no significance).
The binding of UT-A1 was examined by Western blot analysis
of the eluted material. Galectin proteins are predicted to bind
only the high glycosylation form of 117 kDa, as the 97 kDa form
exhibits only immature high mannose Gal-deficient N-glycans
(Chen et al., 2011 and Figure 1). As shown in Figure 2A, we
found that the 117 kDa form of UT-A1 from control rat IM
binds to primarily Gal-3 and Gal-7 with a small amount binding
to Gal-8 and Gal-9C. However, we observed increased binding
of the 117 kDa UT-A1 to Gal-3, -7, -8, and -9, particularly the
enhanced binding to Gal-8 and -9 indicating that the N-glycans
are changed on UT-A1 in diabetic rat kidney. The increased
UT-A1 bound to Gal-3, -7, -8, and -9 is not because of protein
overloading since UT-A1 bound to Gal-1 and -4 is not increased.
Figure 2B shows the signal quantification and statistical analysis
from three independent studies. Galectin-9 has two carbohydrate
recognition domains (CRD). Since GST-Gal-9 is aggregated in
the bacteria, we prepared N-terminal and C-terminal CRDs
separately as GST-Gal-9N (residues 1–148) and GST-Gal-9C
(residues 225–355) (Poland et al., 2011). Only C-terminal, but
not N-terminal, CRD in galectin-9 interacted with UT-A1.
Additionally, we observed that the 117 kDa form of UT-A1 from
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diabetic tissue migrates further upon electrophoresis, reflecting
different glycosylation modifications occurred in the diabetic
animal.
General RNA-seq Results
In order to reveal potential genes and mechanisms that are
involved in UT-A1 glycosylation modification, we performed the
RNA-Seq by using RNA samples from control (n = 3) and STZ
rat (n = 3) IM tip. RNA-Seq generated an average of 14.2 ± 1.44
(mean± SD) million reads per sample (Supplemental Table S1).
About 50 ∼ 70% of the reads were mapped to the rat reference
genome rn4 by STAR. Among a total 25,809 genes annotated in
Ensembl RGSC3.4, 8197 genes had enough reads and therefore
were selected for DESeq analysis, which determined 552 genes as
significantly different (FDR< 0.05) between the control and STZ
rats. Supplemental Figure S1 shows the volcano plot analysis of
differentially expressed genes in normal and STZ rat IM. Table 1
lists the top 15 most significantly up- or down-regulated genes by
log2 fold change in kidney IM tip under diabetic condition.
Functional category and pathway analysis of diabetes-
dependent changed genes were further evaluated by using
IPA (Ingenuity Pathways Analysis, www.ingenuity.com). The
upregulated and downregulated networks under diabetes are
presented in Supplemental Tables S2, S3. Unfortunately, the IPA
analysis did not pick up the glycosylation-related genes, either
the data set does not have such genes or the IPA may not
have glycosylation pathways. We therefore manually searched
and summarized those genes from RNA-seq data involved in
sialylation, fucosylation, glycan chain branching, and glycan
binding protein galectins.
The Mgat Family of
Acetylglucosaminyltransferases
GlcNActransferase (Mgat) enzymes belong to the family of
glycosyltransferases. By the addition of N-acetylglucosamine to
the N-linked sugar chains, Mgat enzymes catalyze the formation
of tri- and multi-antennary branching structures in the Golgi
apparatus (Rini et al., 2009; Stanley et al., 2009). As shown in
TABLE 1 | The top 15 up- and down-regulated genes in STZ rat IM by RNA-seq analysis.
Gene Description Fold change (log2) p-value FDR
UP-REGULATED GENES
Ctse Cathepsin E 4.9 4.01E-55 3.29E-51
Wfdc6b WAP four-disulfide core domain 6B 4.8 8.37E-25 1.37E-21
Lypd2 Ly6/Plaur domain containing 2 4.4 6.92E-22 7.09E19
Pon3 Paraoxonase 3 4.1 1.98E-23 2.32E-20
RGD1563047 BPI fold containing family B, member 1 3.4 9.05E-06 5.31E-04
Fam111a Family with sequence similarity 111 3.4 5.77E-19 3.15E-16
St3gal4 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 3.4 4.17E-30 1.14E-26
Upk3a Uroplakin 3A 3.3 9.11E-17 3.93E-14
Wfdc10 WAP four-disulfide core domain 10 3.3 3.87E-10 7.56E-08
Slc13a2 Solute carrier family 13 2.8 2.88E-21 2.62E-18
Oas1f 2′–5′ oligoadenylate synthetase 1F 2.8 2.59E-05 1.27E-03
RGD1564463 Similar to Mdes protein 2.8 3.82E-06 2.70E-04
Rarres2 Retinoic acid receptor responder 2 2.7 1.49E-23 2.03E-20
Acer2 Alkaline ceramidase 2 2.7 3.14E-03 4.74E-02
Alox15b Arachidonate 15-lipoxygenase, type B 2.5 1.10E-06 8.93E-05
DOWN-REGULATED GENES
Ypel4 Yippee-like 4 (Drosophila) −5.1 2.68E-06 1.96E-04
Umod Uromodulin −3.1 4.92E-27 1.01E-23
Ccl7 Chemokine (C-C motif) ligand 7 −3.1 1.61E-36 6.60E-33
Mucdhl Mucin and cadherin like −2.6 2.24E-08 3.01E-06
Ifit1 IFN-induced protein with tetratricopeptide repeats 1 −2.5 2.77E-14 9.47E-12
Ifit3 IFN-induced protein with tetratricopeptide repeats 3 −2.5 5.67E-06 3.66E-04
Loxl4 Lysyl oxidase-like 4 −2.5 4.26E-21 3.18E-18
Tff3 Trefoil factor 3, intestinal −2.4 9.13E-07 7.87E-05
Kap Kidney androgen regulated protein −2.2 4.71E-05 2.04E-03
Ifit2 IFN-induced protein with tetratricopeptide repeats 2 −2.2 1.27E-06 1.02E-04
S100a5 S100 calcium binding protein A5 −2.1 2.10E-16 8.60E-14
Egf Epidermal growth factor −2.1 1.32E-13 4.01E-11
Mgp Matrix Gla protein −2.1 8.08E-11 1.84E-08
Zcchc12 Zinc finger, CCHC domain containing 12 −2.1 2.30E-09 3.70E-07
Gpnmb Glycoprotein (transmembrane) −2.0 6.26E-11 1.46E-08
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TABLE 2 | Summary of acetylglucosaminyltransferase genes from kidney IM by RNA-seq analysis.
Gene ID Gene name Average counts p-value FRD
Ctrl STZ
Mgat1 Mannoside acetylglucosaminyltransferase 1 118.0 109.5 0.777 0.945
Mgat2 Mannoside acetylglucosaminyltransferase 2 76.5 103.3 0.127 0.454
Mgat3 Mannoside acetyl glucosaminyltransferase 3 NA* NA
Mgat4a Mannoside acetylglucosaminyltransferase 4, isoenzyme A 48.1 35.8 0.258 0.629
Mgat4b Mannoside acetylglucosaminyltransferase 4, isoenzyme B NA NA
Mgat4c Mannosyl (α-1,3-)-glycoprotein β-1,4-N- acetylglucosaminyltransferase, isozyme C NA NA
Mgat5 Mannoside acetylglucosaminyltransferase 5 NA NA
Mgat5b Mannoside acetylglucosaminyltransferase 5, isoenzyme B NA NA
*Indicate no or very low non-reliable calculation.
Figure 1, UT-A1 from diabetic rats undergoes increased glycan
branching, indicated by its affinity to lectin PHA-L.We examined
N-glycan branching enzyme Mgat expression in the kidney.
Table 2 lists the Mgat genes expressed in kidney IM according to
the RNA-seq analysis. Three Mgat enzymes (Mgat1 > Mgat2 >
Mgat4a) were highly expressed in kidney IM. However, the
transcripts of Mgat gene in the kidney did not change, indicating
that changes in UT-A1 glycan branching may not be due to
changes in Mgat transcription levels. Mgat3, Mgat4b, Mgat4c,
Mgat5, and Mgat5b were not expressed (or are expressed at very
low levels) in kidney IM.
Sialyltransferases and Neuraminidases
As reported before (Chen et al., 2011) and shown in the
current study (Figure 1), UT-A1 contains a high amount of
SNA-bound sialic acid in its glycan structure under diabetic
situations (Figure 1). We recently reported that modification
with sialic acid increases UT-A1 membrane stability and
urea transport activity (Li et al., 2014). Here, we explored
sialylation related enzymes in diabetes. There are three
categories of sialyltransferases. In the type I enzyme family
of α-2, 3 sialyltransferases, St3gal (ST3 β-galactoside α-
2, 3-sialyltransferase) variants 2, 4, and 6 are found in
kidney IM (Table 3). The most prominently expressed α-2, 3
sialyltransferase in the kidney IM region is St3gal6, however
it did not change under the diabetic condition. The most
significant increased sialyltransferase is St3gal4 (q = 1.14E-
26) in diabetes. There is no change for St3gal2 and ST3gal6. In
the type II enzyme family of α-2, 6 sialyltransferases, ST6gal1,
St6galnac2, and 3 are highly expressed in kidney IM but they
did not change in diabetes. Clearly, RNA-seq analysis showed
that kidney IM does not express (or expresses at very low
levels) the members of the type III enzyme family of α-2,8
sialyltransferases.
Glycoprotein sialylation is reversely regulated by
neuraminidase (sialidase). Sialidases hydrolyze terminal
sialic residues in glycoproteins and reduce protein sialylation.
There are four neuraminidases (Neu). RNA-Seq analysis revealed
that only Neu1 is expressed in kidney IM. The Neu1 enzyme
transcript shows an increasing tendency but no significant
increases under diabetic conditions (Table 3).
Glycoprotein Fucosylation and
Fucosyltransferases
Lectin pulldown assay in Figure 1 showed an increase of UT-
A1 fucosylation pulled down by AAL in diabetes. Glycoprotein
fucosylation is mediated by fucosyltransferases. There are more
than eight fucosyltransferases in mammals. Surprisingly, RNA-
Seq analysis (Table 4) shows that the kidney IM only expresses
the α-1,6 fucosyltransferase 8 (Fut 8) mRNA isoform. Fut 8
catalyzes fucose residue transfer within the Golgi apparatus from
GDP-fucose to the innermost GlcNAc residue of hybrid and
complex N-glycan via α 1,6-linkage (termed core fucosylation)
(Nishikawa et al., 1992). The Fut 8 transcript is decreased but
does not reach statistical significance in diabetes. Kidney IM does
not express the peripheral α-1,3-fucose enzymes of Fut1, 2, 4, 7,
9, 10, and 11.
Glycan Binding Protein Galectin
The galectin family is defined by having at least one characteristic
CRD with an affinity for beta-galactosides (Rabinovich
et al., 2007). Carbohydrate structure changes often affect a
glycoprotein’s binding affinity for the galectin proteins. By their
association with glycans, galectin proteins play many important
roles in regulating glycoprotein function. There have been
15 galectins discovered in mammals, encoded by the LGALS
genes (Cummings and Liu, 2009). Galectins are divided in three
categories based on their distinct structures: the prototypical,
chimera, and tandem galectins. RNA-seq analysis showed four
types of galectin genes are expressed in a high abundance
in kidney IM, Gal-9 > Gal-1 > Gal-3 >> Gal-5 (Table 5).
Galectin-1 is highly expressed galectin in kidney IM, however
GST pull-down assay did not show its association with UT-A1
(Figure 1). Moreover, galectin-1 expression did not change in
diabetes. Therefore, galectin-1 is unlikely to regulate UT-A1.
Galectin-9 is abundantly expressed in kidney but its expression
is significantly decreased (p = 0.001, q = 0.019) under diabetic
conditions. Galectin-3 is unique and is the only member of the
chimera galectin group, designated as such because it has an
extended N-terminus. Figure 2 shows galectin-3 is the major
galectin that binds to UT-A1 under non-stimulated conditions;
this binding is increased in diabetes. In agreement with the
increased galectin-3 and UT-A1 binding activity, galectin-3 gene
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TABLE 3 | Summary of sialyltransferase and neuraminidase genes from
kidney IM.
Category Gene name Average counts p-value FRD
Ctrl STZ
α2,3 sialyltransferase St3gal1 NA NA
St3gal2 33.1 38.2 0.623 0.886
St3gal3 NA NA
St3gal4 52.8 542.5 4.17E-30 1.14E-26
St3gal5 NA NA
St3gal6 289.4 289.2 0.982 1.000
α2,6 sialyltransferase St6gal1 166.5 125.8 0.108 0.416
St6galnac1 NA NA
St6galnac2 34.4 45.3 0.317 0.685
St6galnac3 58.6 82.8 0.088 0.374
α2,8-sialyltransferase St8sia1 NA NA
St8sia2 NA NA
St8sia3 NA NA
St8sia4 NA NA
St8sia5 NA NA
St8sia6 NA NA
Neuraminidase (Sialidase) Neu1 6.4 13.6 0.146 0.999
Neu2 NA NA
Neu3 NA NA
Neu4 NA NA
St3gal: ST3 β-galactoside α-2,3-sialyltransferase.
St6galnac: ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide
α-2,6-sialyltransferase.
St8sia: ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase.
expression is increased about ∼1 fold (p = 0.008, q = 0.089).
Galectin-5 was only found in rat and not in any other species.
Kidney IM expresses galectin-5, but its expression level is not
changed in diabetes.
Validation of RNA-seq Results by Real-time PCR
In order to verify those glycosylation related genes identified
by RNA-seq, we performed real-time quantitative PCR (qPCR).
We chose 10 genes and compared their mRNA levels by
qPCR. The primers, prior to using for real-time PCR, were
confirmed by regular PCR as amplifying the appropriate bands
and DNA gel electrophoresis showing a single expected size
band (Supplemental Figure S2). Very similar patterns of gene
expression were observed between the RNA-seq and qPCR
analysis, however some differences were observed (Figure 3).
Magt4a was found increased by qPCR but not by RNA-Seq.
Discussion
In the current study, we show an important finding that
under a diabetic condition, UT-A1 protein glycan structure is
dramatically changed. UT-A1 glycan undergoes increased
sialylation, fucosylation, and glycan branching. This is
consistent with a recent work done by Ravidá et al. (2015)
TABLE 4 | Summary of fucosyltransferase genes from kidney IM by
RNA-seq analysis.
Gene ID Gene name Average counts p-value FRD
Ctrl STZ
ALPHA (1,3) FUCOSYLTRANSFERASE
Fut1 Fucosyltransferase 1 NA NA
Fut2 Fucosyltransferase 2 NA NA
Fut4 Fucosyltransferase 4 NA NA
Fut7 Fucosyltransferase 7 NA NA
Fut9 Fucosyltransferase 9 NA NA
Fut10 Fucosyltransferase 10 NA NA
Fut11 Fucosyltransferase 11 NA NA
ALPHA (1,6) FUCOSYLTRANSFERASE
Fut8 Fucosyltransferase 8 76.0 51.8 0.061 0.313
TABLE 5 | Summary of galectin genes from kidney IM by RNA-seq
analysis.
Gene ID Gene name Average counts p-value FRD
Ctrl STZ
Lgals1 Galectin-1 (Gal-1) 732.9 808.1 0.738 0.935
Lgals2 Galectin-2 (Gal-2) NA NA
Lgals3 Galectin-3 (Gal-3) 117.6 209.4 0.008 0.089
Lgals4 Galectin-4 (Gal-4) NA NA
Lgals5 Galectin-5 (Gal-5) 6.3 6.6 0.959 0.999
Lgals7 Galectin-7 (Gal-7) NA NA
Lgals8 Galectin-8 (Gal-8) NA NA
Lgals9 Galectin-9 (Gal-9) 848.4 434.2 0.001 0.019
Lgals12 Galectin-12 (Gal-12) NA NA
showing increased glycosylation modification of glycoproteins
by terminal glucose/N-acetylglucosamine (Glc/GlcNAc),
galactose/N-acetylgalactosamine (Gal/GalNAc), and fucose
during disease progression of STZ-induced diabetic rat kidney
cortex. Since kidney IMCD has enhanced urea permeability in
diabetes (Kim et al., 2003; Pech et al., 2005), which prevents
glucosuria-induced water loss, we proposed that glycosylation
modification of UT-A1 by sialylation, fucosylation and branching
may play an important role in regulating kidney IMCD urea
reabsorption, particularly in diabetes. Although the role of
glycosylation in regulating glycoprotein function has been
appreciated for decades, the question of how glycosylation affects
transporter activity remains unknown. Our findings indicate that
when studying the regulatory function of protein glycosylation,
we should go deeper to investigate how changes in the sugar
component of the glycan structure may affect the glycoprotein
function. Deciphering the code of each different oligosaccharide
in the glycan chain may unravel how glycosylation modulates
glycoprotein function.
Glycosylation is thought to be the most complex post
translational modification because of the large number of
enzymatic steps involved in glycan biosynthesis, glycan
extension, modification, recognition, and catabolism (Nairn
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FIGURE 3 | Quantitative real-time PCR assays. RNAs were prepared from IM tip (n = 3/group) and subjected to quantitative PCR (qPCR) assays using the
fluorescent dye SYBR Green. The target gene mRNA levels were normalized to GAPDH. Relative mRNA levels of the target gene in STZ rats were compared to the
control rats, where the expression was set to 1.0 (n = 3; values represent mean ± SD). A paired Student’s t-test was used to assess statistically significant differences
(compared to control *P < 0.05; **P < 0.01; NS, no significance).
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et al., 2008). Different forms of glycosylation are mainly due
to the different processing after α-mannosidase digestion by
the sequential action of specific glycosyltransferases, which
generates the diverse glycoproteins. These diversities include
distinct glycan composition (the types of sugars that are
linked to a particular protein), glycan structure (branched
or unbranched chains) and glycan length (short- or long-
chain oligosaccharides). Therefore, any changes of glycan
structure, length or sugar composition might affect glycoprotein
functions.
Diabetes causes an increased UT-A1 protein abundance that
has been recognized for years (Kim et al., 2003). The finding
in this study that diabetes also causes UT-A1 glycan structure
change prompts us to go to the deeper questions of how
the glycan structure alteration affects UT-A1 protein function.
As glycosylation is a complex process with more than 200
enzymes in 40 families (Nairn et al., 2008), to study the UT-
A1 glycosylation-related genes, we employed an RNA-Seq assay.
Glycan sialylation, fucosylation and branching are the three
most common and important maturation processes for N-
glycosylation, and these processes all occur in the Golgi complex.
In this study, we are particularly interested in those enzymes
involving UT-A1 glycan sialylation, fucosylation and branching.
Mgat enzymes are essential for the synthesis of hybrid and
complex N-glycans, and are involved in N-glycan branching
(Nishikawa et al., 1992; Lau et al., 2007; Zhao et al., 2008).
Mgat3 catalyzes the addition of GlcNAc in beta 1-4 linkage
to the beta-linked mannose of the tri-mannosyl core of N-
linked sugar chains (Lau et al., 2007; Xu et al., 2012). The
Mgat5 enzyme catalyzes tetra-antennary β1, 6GlcNAc-branched
and is preferentially elongated with poly N-acetyllactosamine
(Hirabayashi et al., 2002; Lau et al., 2007; Zhao et al., 2008).
Mgat1, Mgat2, and Mgat4a are expressed in the kidney IM,
the specific portion where UT-A1 is located. Under diabetic
conditions, UT-A1 pulled down by PHA-L exhibits greater glycan
branching (Figure 1). But RNA-seq analysis shows that Mgat
gene expression does not increase in diabetes. We presume that
UT-A1 glycan branching is not regulated at the transcriptional
level but at the protein level or by increased enzyme activity. It
should be noted that gene expression patterns do not necessarily
correlate with protein levels (Fessler et al., 2002; Sharif et al.,
2007). Alternatively, UT-A1 branching may be determined by
substrate concentration. Indeed, in diabetes, the hexosamine
pathway is elevated and hexosamine secretion in urine is
high (Fushimi et al., 1974). The increased blood glucose and
hexosamine concentrations could change UT-A1 glycosylation
and lead to increased UT-A1 glycan branching. However, our
qPCR data show that there is an increase of Mgat4a in diabetes,
which could, together with other Mgat enzymes, promote UT-
A1 glycan branching. Future studies are required to address this
issue.
Glycoprotein sialylation is enhanced by sialyltransferases and
reduced by neuraminidases (also called sialidases). We recently
reported that sialylation increases UT-A1 urea transport activity
(Li et al., 2014). In diabetes, UT-A1 glycan has increased
sialylation pulled down by SNA (Figure 1), suggesting that the
sialylation modification may have critical regulatory roles in
UT-A1 bioactivity. There are three types of sialyltransferases
which mediate α2,3, α2,6, and α2,8 sialic acid linkages,
respectively. Our data show that kidney IM does not express
α2,8 sialyltransferases. The α2,8 sialyltransferases St8sia2 (STX)
and St8sia4 (PST) have been found to be highly expressed in
brain (Rieger et al., 2008). RNA-seq analysis suggested that
kidney UT-A1 sialylation may be mediated by α2,3 and α2,6
sialyltransferases. St3gal6 is the most highly expressed α2,3
sialyltransferases in kidney IM; however, St3gal4 is the most
significantly changed α2,3 sialyltransferases in diabetes, and may
be responsible for the increased UT-A1 sialylation.
The extent of glycoprotein sialylation can be negatively
regulated by sialidases, which catalyze the hydrolysis of terminal
sialic acid residues (Monti et al., 2002). At least four mammalian
sialidase homologs have been described in the human genome
(Neu1, Neu2, Neu3, Neu4). Igdoura et al. reported that Neu1 is
highly detected in kidney (Igdoura et al., 1998). Consistent with
the literature, we show in this study that kidney IM expresses
Neu1. Three other neuramidase forms were undetectable in
kidney. Based on the RNA-seq results, kidney UT-A1 sialylation
might bemediated by sialyltransferase St3gal4 and/or St3gal6 and
contracted by sialidase Neu1. However, direct evidence will be
required to verify this in the future.
There are two major types of glycoprotein fucosylation
enzymes, alpha (1,3) fucosyltrans-ferase and alpha (1,6)
fucosyltransferase. Enhanced fucosylation levels of glycoproteins
have been previously observed in both human and experimental
diabetes (Poland et al., 2001; Itoh et al., 2007). Fut8 is the
only member of the alpha (1,6) fucosyltransferase family and
is a membrane-bound protein in the trans cisternae of the
Golgi. Fut8 catalyzes the addition of fucose in the alpha 1,6
linkage to the first GlcNAc residue and form core fucosylation
(Ferrara et al., 2011). Interestingly, Nairn et al reported that
glycan structures containing terminal fucose residues are highly
abundant in kidney (37%) and brain (19%), but have extremely
low abundance in liver and testis (<4%) (Nairn et al., 2008).
It is of interest that kidney IM only expresses Fut8 but no
other fucosyltransferase. We tried to clone all fucosyltransferase
genes from kidney previously, but only obtained Fut8. Our
RNA-Seq study confirmed that kidney IM actually only has Fut8.
Therefore, we propose that kidney UT-A1 fucosylation is the
core fucosylation which is pulled down by lectin AAL (Figure 1)
and is most likely mediated by Fut8.
By binding glycan and forming a galectin-glycan lattice,
galectin proteins play many important roles in regulating
glycoprotein functions, such as stabilizing glycoproteins at the
cell surface, preventing endocytosis and increasing protein
stability (Rabinovich et al., 2007; Garner and Baum, 2008).
Each galectin has different biological roles and recognizes
different glycan structures (Stowell et al., 2008). Glycan changes
often affect galectin and glycoprotein bindings. In Figure 2,
we show galectin 8 does not bind to UT-A1 under normal
conditions. However, during diabetes UT-A1 glycan is changed
(Figure 1) and galectin-8 could bind to UT-A1 (Figure 2).
Multiple galectin proteins are found in kidney IM. UT-A1 can
bind to multiple galectins particularly in diabetic conditions.
This suggests that UT-A1 could be regulated by multiple galectin
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proteins and different galectin binding may regulate UT-A1
in different aspects. We therefore propose that the formation
of galectin-glycan lattices of UT-A1 binding to galectin at the
cell surface leads to accumulation of functional UT-A1 on
the plasma membrane and therefore increases urea transport
activity.
In summary, diabetes has increased urea permeability
mediated by urea transporter UT-A1 in kidney IMCD. This
is consistent with increased UT-A1 protein abundance, in
particular, the highly glycosylated 117 kDa form. In the current
study, we show UT-A1 glycan undergoes increased sialylation,
fucosylation and branching in a diabetic model. This suggests
that modulation of glycan composition or structure could
alter UT-A1 function. By employing RNA-seq technology, we
profiled glycosylation related gene expression in kidney IM
under diabetic conditions and identified some crucial genes that
may mediate UT-A1 glycosylation alteration. It is important
to note that in our experiments the mapped reads were
relatively low. Some low expressed genes might be missed
in RNA-Seq, such as Mgat3 or St3gal1 which were identified
by PCR. In addition to real-time PCR, other experimental
methods such as Northern blot and Western blot should be
employed to provide more detailed information about these
potentially important genes and gene products, as well as using
immunohistochemistry to investigate their co-localization with
UT-A1 and siRNA knockdown to verify their functional link.
Future studies to characterize those glycosylation related genes
will undoubtedly provide new insights into the understanding
of how glycosylation alters UT-A1-mediated urea transport in
diabetes.
Data Deposition
The RNA-seq data have been deposited in GEO with the
accession number GSE69548.
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